thus we could compare the new CF with the laboratory's current CF; when no methodology modifications were introduced since the time of the last calibration, we obtained highly concordant CFs (Supplementary Table 6 ).
For appropriate clinical decisions, we need to judge agreement between the methods after IS conversion; to this aim, we interchanged 41 whole blood samples (divided into two parts) from CML patients with Lab#09. The concordance in MR IS between the reference method and the external laboratory was 88% after conversion (36 out of 41 samples were in the same MR category) (Figure 2c ). This result underlines the importance of conversion to the IS, given that after harmonization we were able to halve the number of discordant data (from nine to five cases).
In the present study, we show that secondary reference biological calibrators anchored to the WHO primary standards can decrease inter-laboratory variability. Our results, together with those recently reported by Cross et al., 11 substantiate the objective initially set during the establishment of the WHO primary standards, that is, to facilitate worldwide diffusion of the IS. For the first time in Latin America, this study provides a platform on which to assess the performance of distinct clinical BCR-ABL1 tests and confirm the utility of secondary reference materials to further improve IS accuracy and inter-laboratory precision. This effort will continue in the future by providing secondary reference material to the centers involved in this project and potential new participants; moreover, due to its higher precision and absolute quantification capability, we are evaluating the possibility of including digital PCR as the calibration method for the future.
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MS
1,2 Human leukocyte antigen (HLA) proteins initiate immune surveillance through peptide presentation to T-cell receptors. 3 Each HLA allele has the capability of presenting a differing limited repertoire of peptides derived from self and non-self proteins, therefore HLA polymorphim has been associated with numerous immunemediated diseases. 4 A genome-wide association study (GWAS) of MM identified a risk variant within the major histocompatibility complex Accepted article preview online 27 July 2016; advance online publication, 19 August 2016 (MHC), but the associated single-nucleotide polymorphism (SNP; rs228580) was not directly characterized with classical HLA typing. 5 GWAS has identified loci in the major histocompatibility region as the strong associations in other B-cell malignancies, with P-values of up to 10 − 60 . 6 Previous MM association studies with HLA are limited by sample size. 7 Building on work in chronic lymphocytic leukemia (CLL), where a similar analysis identified several HLA alleles associated with susceptibility, 8 Table 1 ). HLA-typing data were available on 2897 White, 569 African American, 184 Hispanic and 74 Asian/Pacific Islander patients. Independent association studies were conducted with 50 000 controls for each ethnic group. Controls were selected randomly from the NMDP volunteer adult donor registry recruited since 2005 and frequency-matched for patient age quartiles and gender proportions. Cases and controls were HLA typed using DNA-based methods (Sanger sequence-based typing or sequence-specific oligonucleotide). 9 Predisposing or protective associations of HLA polymorphisms with MM were identified at: (1) the individual allele level (HLA-A, -C, -B, -DRB3/4/5, -DRB1, -DQB1 loci); (2) haplotype combinations of these loci; and (3) genotypes of the loci. Associations were tested at two levels of HLA-typing resolution -allele family and high resolution. DRBX*NNNN designates absence of any DRB3/4/5 gene on the chromosome. Groups of alleles with identical amino-acid sequence in the antigen recognition site, designated with a 'g' notation, were not distinguished. 10 We developed a novel statistical methodology for fine mapping of HLA associations, previously applied in CLL. 8 We incorporated HLA-typing ambiguity into our statistical model, allowing reporting of high-resolution haplotype-level associations. We also employed factor analysis to group associated HLA variants that are highly correlated by linkage disequilibrium. 11 Multivariate logistic regression on independent sets of cases and controls for each ethnic subgroup identifies HLA that are associated with MM. Figure 1 . High-resolution HLA alleles associated with multiple myeloma among Whites (a) and Asian/Pacific Islanders (b).
Letters to the Editor P-values were adjusted for multiple testing using false discovery rate with a 5% threshold; associations for age and gender interactions were unadjusted. 12 
CASES AND CONTROLS WERE YOUNGER THAN TYPICAL MM PATIENTS
Baseline demographics are summarized in Supplementary Table 1 . Cases and controls are younger (49 years) than the typical median age for MM incidence (69 years). Generalizability of our findings may be limited to younger MM patients and possibly higher-risk disease, where allogeneic HSCT was considered. Figure 1 depicts the high-resolution allele-level associations for Whites (three predisposing or positively associated, and three protective or negatively associated with MM) and Asians (four predisposing). Although no significant high-resolution allelic associations were identified among Africans Americans and Hispanics, several allele family level and haplotypic associations were detected.
ALLELE-LEVEL HLA ASSOCIATIONS IDENTIFIED IN WHITES AND ASIANS
We list all associated haplotypes and alleles at both high-resolution and allele family level for each population, with correlated associations grouped by factor analysis in Supplementary Table 2 . The longest extended haplotypic association within each factor analysis group is provided in Table 1 for each population. Suggestive associations that were no longer significant after correction for multiple testing are listed in Supplementary Table 3. C*07 POSITIVELY ASSOCIATED WITH MM RISK An increased MM risk was observed for both C*07:02 g (odds ratio (OR) = 1.27; P = 5.27 × 10
) and B*07:02 g (OR = 1.24; P = 3.70 × 10 − 5 ) in Whites. Because these two alleles are in extremely high linkage disequilibrium (D'40.98), 10 it was not possible to disentangle effects of these alleles in Whites. We found three haplotypes containing these alleles independently associated with MM: A*03~C*07~B*07~DRB5*01D RB1*15~DQB1*06 (OR = 1.27; P = 0.03), A*03:01 g~C*07:02 g B*07:02 g (OR = 1.33; P = 4.68 × 10
) and C*07:02 g~B*07:02 g~DRB4*01:01 g~DRB1*04:01~DQB1*03:02g (OR = 1.85; P = 0.0497; Table 1A ).
Although neither single allele C*07:02 g nor B*07:02 g was associated with MM in other populations, several extended haplotype associations containing C*07 were positively associated with MM in Hispanics and Asians also. Haplotypes A*24:02 g~C*07:02 g~B*39:06~DRB3*01:01~DRB1*14:06~DQ-B1*03:01 g (OR = 3.93; P = 0.0016) and A*68:02~C*07:01 g~B*57:03 (OR = 2.94; P = 0.039) in Hispanics (Table 1C) , and haplotypes C*07~B*38~DRB5*01~DRB1*15~DQB1*05 (OR = 3.91; P = 0.0094) and C*07:02 g~B*15:35 were associated in Asians (OR = 8.99; P = 2.23 × 10
; Table 1D ). Because C*07, but Figure 1 ), with higher risk observed when C*02:02 g occurred on a haplotype lacking a DRB3/4/5 gene, C*02:02 g~DRBX*NNNN (OR = 1.50; P = 0.042; Table 1A ). Among African Americans, two independent haplotype associations (C*04~B*15 and DRB3*02~DRB1*11~DQB1*02) were associated with the increased risk of MM (Table 1B) .
We tested for interactions of HLA associations with age (Supplementary Table 4 ) and gender (Supplementary Table 5 ). None of the associations had a gender effect. Genotypic associations, grouped by factor analysis, are listed in Supplementary Table 6 .
With the large numbers of cases/controls across four population groups, this study represents the most extensive examination of associations of HLA variants with MM risk. Our results using classical HLA typing and haplotype inference clarify findings from a recent GWAS in Northern European Whites (4692 MM cases and 10 990 controls), where HLA alleles were imputed from MHC region SNPs. 5 The most significant GWAS association was DRB5*01 (OR 1.22; P = 1.42 × 10 − 5 ), whereas C*07:02 g and B*07:02 g were also listed as apparently independent MM risk factors in the GWAS. We confirmed these three risk alleles, and illustrate their high correlation by linkage disequilibrium in Whites. Crosspopulation analysis suggests C*07 as the independent risk allele, whereas B*07:02 and DRB5*01 are likely surfacing on the same haplotype rather than contributing to MM risk. Similarly, confirmed were the protective association with MM of C*05:01 g and B*44:02 g alleles occurring on the same haplotype in Whites, and the predisposing associations of C*12:03 g~B*38:01 haplotype and B*58:01 g in Whites and Asians, respectively (Supplementary Table 2 ). Although the cause of the positive risk association for C*07:02 is unclear from our data, it is known that C*07 group alleles have the lowest levels of expression among HLA-C alleles, which reduces the immune control of HIV and may likewise reduce the control of MM.
13 C*07:02 is also a C1 group ligand for inhibitory killer-cell immunoglobulin-like receptor 2DL2/2DL3 receptors on natural killer cells, and this killer-cell immunoglobulin-like receptor/HLA genotype combination has been associated with increased risk of melanoma. 14 The HLA associations observed here and in GWAS demonstrate that the HLA region is a key risk locus for mature B-cell malignancies. 15, 16 MM etiology often involves clonal immunoglobulin production directed against post translationally modified human proteins, such as hyperphosphorylated paratarg-7 or sumoylated Hsp90. 17, 18 HLA presentation of altered self-antigens derived from these modified proteins within B cells to T-cell receptors could stimulate the production of autoantibodies. Additional research is needed to characterize differences among HLA alleles in presentation of these altered self-antigens and to identify additional antigenic targets of MM clones. 19 Although inherited variation in immunologic response to proteinderived peptides may explain some of the increased risk of MM, because odds ratios for HLA were modest, genetic differences within oncogenes probably account for most of this differing risk. Interactions between HLA variants and myeloma subtypes/somatic mutations may also impact efficacy of emerging immunotherapy in MM. 20 Identification of MM associated peptides bound by HLA alleles would be important next steps in developing immune oncologic therapies in MM.
